Neumora Therapeutics (NMRA) Invested Capital (2022 - 2026)

Neumora Therapeutics' Invested Capital history runs 5 years deep, the most recent figure standing at $123.6 million for Q1 2026.

• In Q1 2026, Invested Capital fell 45.86% year-over-year to $123.6 million; the TTM figure through Mar 2026 stood at $123.6 million (down 45.86% YoY), while the FY2025 annual figure was $158.4 million, down 44.82% from the prior year.
• Invested Capital was $123.6 million for Q1 2026 at Neumora Therapeutics, down from $158.4 million in the prior quarter.
• In the past five years, Invested Capital ranged from a high of $512.7 million in Q3 2023 to a low of -$513.5 million in Q2 2023.
• Historically, Invested Capital has averaged $90.7 million across 5 years, with a median of $182.9 million in 2025.
• The sharpest annual moves came in 2023 and 2025: Invested Capital surged 221.49% in 2023, then sank 58.79% in 2025.
• A 5-year view of Invested Capital shows it stood at -$446.8 million in 2022, then surged by 204.97% to $469.1 million in 2023, then tumbled by 38.8% to $287.1 million in 2024, then slumped by 44.82% to $158.4 million in 2025, then fell by 21.94% to $123.6 million in 2026.
• The last three Invested Capital figures came in at $123.6 million (Q1 2026), $158.4 million (Q4 2025), and $132.2 million (Q3 2025), per Business Quant data.